The Sjögren's Foundation is happy to share that the U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim's Ofev® (nintedanib), a new therapy for use in patients with chronic fibrosing interstitial lung diseases (ILDs) in which lung fibrosis continues to worsen. This therapy has a specific mention for Sjögren's patients.
The Foundation is proud to have been working with Boehringer Ingelheim and the significant impact this therapy will have for Sjögren's patients in need. Thank you for all your support of the Foundation as we work with various pharmaceutical companies to develop new therapies to treat Sjögren's.
Click here to learn more
The Sjögren's Foundation is happy to share that the U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim's Ofev® (nintedanib), a new therapy for use in patients with chronic fibrosing interstitial lung diseases (ILDs) in which lung fibrosis continues to worsen. This therapy has a specific mention for Sjögren's patients.
The Foundation is proud to have been working with Boehringer Ingelheim and the significant impact this therapy will have for Sjögren's patients in need. Thank you for all your support of the Foundation as we work with various pharmaceutical companies to develop new therapies to treat Sjögren's.
Click here to learn more